Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant taps Parexel to shepherd retigabine regulatory filings

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Valeant's planned mid-2008 NDA and MAA submissions for the anti-epileptic retigabine will be managed by Parexel. The contract services organization will "develop, coordinate and prepare" the NDA as well as the European MAA, Valeant says. Retigabine, a neuronal potassium-channel opener, is being studied in two international Phase III studies - RESTORE1 and RESTORE2 - as an adjunct treatment for partial onset seizures in patients with refractory epilepsy. Pharmaceutical Approvals Monthly erred in identifying the Phase III program in a previous story (1Pharmaceutical Approvals Monthly May 2007, p. 7). Valeant announced the initiation of a Phase IIa study of retigabine treatment of pain associated with post-herpetic neuralgia on May 31; the proof-of-concept study will enroll 180 patients...

You may also be interested in...



Valeant Targets Cesamet On Breast Cancer As It Waits For Pain Claim

While a chemotherapy-induced neuropathic pain indication is in development, Valeant is relaunching the synthetic cannabinoid Cesamet with a new strategy for its approved antiemetic use that will focus on physicians treating breast cancer at high-volume teaching institutions, President-Valeant North America/R&D Wesley Wheeler told a May 1 earnings call

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.

UsernamePublicRestriction

Register

PS003595

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel